Evommune enrols first subject in chronic inducible urticaria therapy trial
Evommune initiated a Phase II trial of EVO756 to treat chronic inducible urticaria (CIndU) in adults, aiming to assess safety and efficacy in 30 patients with symptomatic dermographism or cold urticaria. The trial uses disease-specific provocation thresholds to measure treatment response, with patients receiving EVO756 orally once daily for four weeks. EVO756, a selective MRGPRX2 antagonist, could offer a new oral treatment for mast cell-mediated diseases and rapidly alleviate itching.
Highlighted Terms
Related News
Evommune initiated a Phase II trial of EVO756 to treat chronic inducible urticaria (CIndU) in adults, aiming to assess safety and efficacy in 30 patients with symptomatic dermographism or cold urticaria. The trial uses disease-specific provocation thresholds to measure treatment response, with patients receiving EVO756 orally once daily for four weeks. EVO756, a selective MRGPRX2 antagonist, could offer a new oral treatment for mast cell-mediated diseases and rapidly alleviate itching.